Loading
Obesity / Type 2 Diabetes Mellitus / Gastric Inhibitory Polypeptide · unknown
Gut Microbes · July 19, 2026
The material analysed did not support any firm read.
This preclinical study identifies LKLKLL, a hexapeptide derived from Akkermansia muciniphila metabolic supernatant, that reduced body weight and improved glucose tolerance in obese and diabetic mouse models through dual GLP-1/GIP modulation. The peptide appears to act via GPR119 receptor interaction and downstream cAMP signaling, offering a defined bioactive component that may inform translational development beyond live bacterial therapy.
In vitro cell culture and in vivo animal model study. STC-1 enteroendocrine cells, high-fat diet-induced obese mice, and diabetic mouse models. Intervention: Hexapeptide LKLKLL derived from Akkermansia muciniphila metabolic supernatant.
Metabolomic profiling identified 54 small molecules in AKK supernatant, including the bioactive hexapeptide LKLKLL LKLKLL reduced body weight in high-fat diet-induced obese mice LKLKLL improved glucose tolerance in diabetic models
No information on dose-response relationships or peptide pharmacokinetics
The identification of a specific peptide component may enable more controlled therapeutic development than live probiotic approaches, but human safety, efficacy, and pharmacokinetic data are required before clinical application. The dual GLP-1/GIP modulation mechanism differs from current GLP-1 agonist therapies and warrants investigation in human metabolic disease.
Without an abstract, there is insufficient information to assess the evidence quality, study design, methodology, or clinical relevance of this peptide research.
As stated by the source record.
Quoted from the source exactly as published.
The identification of a specific peptide component may enable more controlled therapeutic development than live probiotic approaches, but human safety, efficacy, and pharmacokinetic data are required before clinical application. The dual GLP-1/GIP modulation mechanism differs from current GLP-1 agonist therapies and warrants investigation in human metabolic disease.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The ability of Akkermansia muciniphila (AKK) to ameliorate metabolic dysfunction has attracted increasing attention as a potential strategy for obesity and diabetes management. Moving beyond the use of live bacteria toward the identification of defined bioactive components may facilitate translational development. In this study, we found that the metabolic supernatant of AKK promoted GLP-1 and GIP secretion in STC-1 cells. Metabolomic profiling identified 54 small molecules in the AKK supernatant, among which a bioactive hexapeptide, LKLKLL, was identified. LKLKLL reduced body weight in high-fat diet-induced obese mice, improved glucose tolerance in diabetic models, enhanced GLP-1 secretion, and reduced GIP levels. Mechanistically, our data suggest that LKLKLL may interact with GPR119 and activate the Gαs/adenylate cyclase/cAMP signaling pathway, leading to increased intracellular Ca²⁺ levels. Together, these findings identify an AKK-derived peptide with GLP-1/GIP regulatory activity and provide a foundation for further investigation of its potential role in metabolic diseases modulation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.